Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

Abstract

Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF). TFF produces brittle matrix nanostructured aggregates that are sheared into respirable low-density microparticles upon aerosolization from a passive dry powder inhaler. In vitro aerodynamic testing demonstrated that drug loading and excipient type affected the aerosol performance of remdesivir. Remdesivir combined with optimal excipients exhibited desirable aerosol performance (up to 93.0% FPF< 5 µm; 0.82 µm mass median aerodynamic diameter). Remdesivir was amorphous after the TFF process, which benefitted drug dissolution in simulated lung fluid. TFF remdesivir formulations are stable after one month of storage at 25 °C/60% relative humidity. An in vivo pharmacokinetic evaluation showed that TFF remdesivir–leucine was poorly absorbed into systemic circulation while TFF remdesivir-Captisol® demonstrated increased systemic uptake compared to leucine. Remdesivir was hydrolyzed to the nucleoside analog GS-441524 in the lung, and levels of GS-441524 were greater in the lung with leucine formulation compared to Captisol®. In conclusion, TFF technology produces high-potency remdesivir dry powder formulations for inhalation that are suitable to treat patients with COVID-19 on an outpatient basis and earlier in the disease course where effective antiviral therapy can reduce related morbidity and mortality.

Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae

“…Clinical trials examining inhalation-based delivery of remdesivir are currently under way [77,78], though details of this aerosol formulation and whether or not it contains SBECD are not provided. A study of a powder aerosol formulation of remdesivir has also been recently published [79]. These studies overall indicate the clinical interest in the development of an inhalation-based treatment for COVID-19.…”

Resveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Replication In Vitro

“…Although not yet tested, these strategies might also further enhance the potency of pterostilbene. Adjacent to the improved bioavailability, some of these techniques allow drug directed and local delivery of resveratrol or pterostilbene to the primary site of active SARS-CoV-2 replication using inhalation-based systems, which are currently considered as a favorable future strategy for the treatment of COVID-19 (44).…”

Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems

“…Recently, a group of researchers at the University of Texas at Austin succeeded in developing a dry powder inhalation of remedesivir, abroad spectrum antiviral agent, for non-hospitalized COVID-19 patients. Researchers said that the developed new formulation produced using the thin film freezing technology could deliver a low drug dose that tackles the disease in its early stages and targets COVID-19 directly in the lungs [ 152 ].…”